OPRX OptimizeRx Corp

OptimizeRx Sets Third Quarter 2020 Conference Call for Monday, November 9, 2020 at 4:30 p.m. ET

OptimizeRx Sets Third Quarter 2020 Conference Call for Monday, November 9, 2020 at 4:30 p.m. ET

ROCHESTER, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Monday, November 9, 2020 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2020. OptimizeRx management will host the call, followed by a question and answer period.

As , the company expects to report record revenue for the quarter of more than $10.0 million, up over 100% from the same year-ago quarter, along with positive non-GAAP net income.

On the call, management will review how this growth has been driven organically by a combination of enterprise deals and tactical programs, as the company’s life science customers increasingly see the value in transparent access to physicians and patients provided by the OptimizeRx Digital Health Platform.

The full financial results for the quarter will be issued in a press release prior to the call.

Conference Call Information

Date: Monday, November 9, 2020

Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)

Toll-free dial-in number: 1-800-430-8332

International dial-in number: 1-323-347-3277

Conference ID: 9818386

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day through November 30, 2020, as well as available for replay via the Investors section of the OptimizeRx website at .

Toll-free replay number: 1-844-512-2921

International replay number: 1-412-317-6671

Replay ID: 9818386

About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on ,  or visit . 

Important Cautions Regarding Forward Looking Statements        

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact 

Doug Baker, CFO

Tel (248) 651-6568 (x807)

 

Media Contact

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070

Investor Relations Contact 

Ron Both, CMA 

Tel (949) 432-7557 

EN
26/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OptimizeRx Corp

 PRESS RELEASE

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025...

OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will...

 PRESS RELEASE

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Direct...

OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors WALTHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the appointment of Steve Silvestro, currently serving as the Company’s Chief Executive Officer, to its Board of Directors, effective as of June 20, 2025. Mr. Silvestro joined the Company in 2019 and has been the Company’s CEO since March 2025, after serving as the interim...

 PRESS RELEASE

OptimizeRx to Participate in Upcoming Investor Conferences

OptimizeRx to Participate in Upcoming Investor Conferences WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: B. Riley Securities 25th Annual Investor Conference, Marina del Rey, May 21 – 22, 2025Stifel 2025 Boston Cross Sector 1x1 Conference, Boston, June 3 – 4, 202545th Annual William Blair Growth ...

 PRESS RELEASE

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fi...

OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HC...

 PRESS RELEASE

OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) R...

OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibilities as a corporate ci...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch